Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 69,811	$ 47,730
Investments in marketable securities, current	194,285	220,499
Prepaid expenses and other current assets	6,211	7,136
Total current assets	270,307	275,365
Restricted cash	1,716	1,716
Investments in marketable securities, non-current	0	15,322
Property and equipment, net	33,070	22,630
Operating lease right-of-use assets	4,014	5,580
Other assets	889	1,289
Total assets	309,996	321,902
Current liabilities:
Accounts payable	1,992	2,608
Accrued compensation	1,314	3,799
Accrued research costs	596	720
Accrued expenses and other current liabilities	7,317	1,871
Operating lease liabilities, current	3,122	4,045
Total current liabilities	14,341	13,043
Operating lease liabilities, non-current	1,419	1,749
Other long- term liabilities	18,012	10,819
Total liabilities	33,772	25,611
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.00001 par value, 10,000,000 shares authorized as of March 31, 2023 and December 31, 2022; and no shares issued and outstanding as of March 31, 2023 and December 31, 2022	0	0
Common stock, $0.00001 par value, 300,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 58,194,818 and 58,221,760 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively	1	1
Additional paid-in-capital	543,029	539,741
Accumulated other comprehensive loss	(469)	(1,048)
Accumulated deficit	(266,337)	(242,403)
Total stockholders’ equity	276,224	296,291
Total liabilities and stockholders’ equity	$ 309,996	$ 321,902